Mede­or’s cell ther­a­py boosts im­mune tol­er­ance in reg­is­tra­tional tri­al of donor kid­ney re­cip­i­ents

Mede­or Ther­a­peu­tics’ Phase III sin­gle-dose cell ther­a­py has seen more than half of a spe­cif­ic group of donor kid­ney re­cip­i­ents stop im­muno­sup­pres­sion ther­a­py for two years, spark­ing plans for an FDA fil­ing.

Mede­or’s MDR-101 is de­signed to in­duce and main­tain a state known as mixed chimerism, which oc­curs when a low lev­el of donor blood cells re­mains in the blood of a donor kid­ney re­cip­i­ent. MDR-101 treat­ment in­volves in­ject­ing blood stem cells and T cells from the donor in­to the re­ceiv­ing pa­tient.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER